New drug cocktail aims to shrink lymphoma tumors without chemo
NCT ID NCT04450173
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a combination of three drugs (obinutuzumab, ibrutinib, and venetoclax) can shrink tumors in people with untreated follicular lymphoma. The trial includes 40 adults with stage II to IV disease. The goal is to see if the combination works better than any single drug alone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANN ARBOR STAGE II FOLLICULAR LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of California Davis Comprehensive Cancer Center
Sacramento, California, 95817, United States
-
University of California, Los Angeles
Los Angeles, California, 90095, United States
-
University of California, San Diego
San Diego, California, 92037, United States
-
University of California, San Francisco (UCSF) Fresno
Fresno, California, 93701, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can two immune boosters outsmart follicular lymphoma without chemo?
- Triple-Drug cocktail aims to boost remission in follicular lymphoma
- New drug combo shows promise for untreated lymphoma patients
- New drug cocktail aims to shrink lymphoma without chemo
- New drug duo aims to control lymphoma without chemo
- New drug combo aims to control lymphoma without chemo